These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 6401427)

  • 1. Pentamethylmelamine (PMM): Phase I clinical and pharmacokinetic studies.
    Muindi JR; Newell DR; Smith IE; Harrap KR
    Br J Cancer; 1983 Jan; 47(1):27-33. PubMed ID: 6401427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of pentamethylmelamine: a clinical and pharmacologic study.
    Ihde DC; Dutcher JS; Young RC; Cordes RS; Barlock AL; Hubbard SM; Jones RB; Boyd MR
    Cancer Treat Rep; 1981; 65(9-10):755-62. PubMed ID: 6791819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of pentamethylmelamine in patients with previously treated malignancies.
    Van Echo DA; Chiuten DF; Whitacre M; Aisner J; Lichtenfeld JL; Wiernik PH
    Cancer Treat Rep; 1980; 64(12):1335-9. PubMed ID: 6781747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of pentamethylmelamine.
    Ajani JA; Cabanillas FF; Bodey GP
    Cancer Treat Rep; 1982 May; 66(5):1227-8. PubMed ID: 6805950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I and pharmacological studies of pentamethylmelamine administered by 24-hour intravenous infusion.
    Casper ES; Gralla RJ; Lynch GR; Jones BR; Woodcock TM; Gordon C; Kelsen DP; Young CW
    Cancer Res; 1981 Apr; 41(4):1402-6. PubMed ID: 6783296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pentamethylmelamine: review of an aqueous analog of hexamethylmelamine.
    Foster BJ; Clagett-Carr K; Hoth D; Leyland-Jones B
    Cancer Treat Rep; 1986 Mar; 70(3):383-9. PubMed ID: 3082512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early clinical trial of a 1-day intermittent schedule for pentamethylmelamine.
    Eagan RT; Creagan ET; Rubin J; O'Connell MJ; Kovach JS
    Cancer Treat Rep; 1980; 64(8-9):993-5. PubMed ID: 6778613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hexamethylmelamine and pentamethylmelamine: an update.
    Hahn DA
    Drug Intell Clin Pharm; 1983 Jun; 17(6):418-24. PubMed ID: 6407810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human central nervous system pharmacology of pentamethylmelamine and its metabolites.
    Stewart DJ; Benvenuto JA; Leavens M; Smith RG; Cabanillas F; Benjamin RS; Loo TL
    J Neurooncol; 1983; 1(4):357-64. PubMed ID: 6432969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized phase II trial of hexamethylmelamine versus pentamethylmelamine in carcinoma of the bilharzial bladder.
    Gad-el-Mawla N; Ziegler JL; Hamza R; Elserafi M; Khaled H
    Cancer Treat Rep; 1984 May; 68(5):793-4. PubMed ID: 6426792
    [No Abstract]   [Full Text] [Related]  

  • 11. A sensitive and specific assay for pentamethylmelamine in plasma: applicability to clinical studies.
    Dutcher JS; Jones RB; Boyd MR
    Cancer Treat Rep; 1980 Jan; 64(1):99-104. PubMed ID: 6769585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of hexamethylmelamine and pentamethylmelamine in mice.
    Broggini M; Colombo T; D'Incalci M; Donnelli MG; Gescher A; Garattini S
    Cancer Treat Rep; 1981; 65(7-8):669-72. PubMed ID: 6788370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hexamethylmelamine and pentamethylmelamine tissue distribution in M5076/73A ovarian cancer-bearing mice.
    Broggini M; Rossi C; Colombo T; D'Incalci M
    Cancer Treat Rep; 1982 Jan; 66(1):127-33. PubMed ID: 6796267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of pentamethylmelamine.
    Goldberg RS; Griffin JP; McSherry JW; Krakoff IH
    Cancer Treat Rep; 1980; 64(12):1319-22. PubMed ID: 6781746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-pass metabolism of pentamethylmelamine in the rat liver.
    Klippert PJ; Hulshoff A; Hofman GA; Noordhoek J
    Cancer Res; 1985 Mar; 45(3):983-6. PubMed ID: 3918792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial and pharmacokinetics of trimelamol (N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine).
    Judson IR; Calvert AH; Rutty CJ; Abel G; Gumbrell LA; Graham MA; Evans BD; Wilman DE; Ashley SE; Cairnduff F
    Cancer Res; 1989 Oct; 49(19):5475-9. PubMed ID: 2670205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific determination of pentamethylmelamine and its demethylated metabolites in human plasma by high pressure liquid chromatography.
    Leyland-Jones BR; Deesen PE; Casper ES; Young CW
    Ther Drug Monit; 1982; 4(2):185-90. PubMed ID: 6808715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low central nervous system penetration of N2,N4,N6,-trihydroxymethyl-N2,N4,N6,-trimethylmelamine (Trimelamol): a cytotoxic s-triazine with reduced neurotoxicity.
    Judson IR; Rutty CJ; Abel G; Graham MA
    Br J Cancer; 1986 May; 53(5):601-6. PubMed ID: 3087399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disposition and metabolism of pentamethylmelamine and hexamethylmelamine in rabbits and humans.
    Ames MM; Powis G; Kovach JS; Eagan RT
    Cancer Res; 1979 Dec; 39(12):5016-21. PubMed ID: 115586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hexamethylmelamine chemotherapy for disseminated endometrial cancer.
    Seski JC; Edwards CL; Copeland LJ; Gershenson DM
    Obstet Gynecol; 1981 Sep; 58(3):361-3. PubMed ID: 6791063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.